< 10% of Eligible Type 2 Diabetes Patients Get New but Pricey Drugs < 10% of Eligible Type 2 Diabetes Patients Get New but Pricey Drugs

Data from 1133 US adults with type 2 diabetes show only 9% received treatment with an SGLT2 inhibitor or GLP-1 agonist in 2017-2020 despite all of them meeting 2022 criteria for receiving these agents.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news